Defining a fibrinogen-to-factor XIII replacement ratio in an in-vitro model of dilutional coagulopathy [0.03%]
定义稀释性凝血障碍体外模型中的纤维蛋白原与因子ⅩIII替代比率
Cristina Alomar-Dominguez,Marie Therese Bauer,Dietmar Fries et al.
Cristina Alomar-Dominguez et al.
Background: Massive blood loss during surgery or trauma leads to dilutional coagulopathy. While fibrinogen is typically the first factor to reach critical levels, factor XIII (FXIII) also decreases proportionally, further...
Inhibition of inflammation reduces hypofibrinolysis in severe COVID-19: A nested case-control study within the MaastrICCht cohort [0.03%]
抑制炎症可减少严重COVID-19患者的低纤维蛋白溶解作用：MaastrICCht队列中的病例对照研究
Joep Schellens,Magdolna Nagy,Anne-Marije Hulshof et al.
Joep Schellens et al.
Background: Critically ill COVID-19 patients exhibit a hypercoagulable and hypofibrinolytic phenotype, further characterized by a prolonged clotting time in rotational thromboelastometry (ROTEM) measurements. We investiga...
Treatment strategies, bleeding, long-term recurrence and mortality in abdominal vein thrombosis: Findings from the TROLL registry [0.03%]
肝静脉血栓形成的治疗策略、出血、长期复发和死亡的危险因素：来自TROLL登记处的研究结果
Camilla Tøvik Jørgensen,Nicoletta Riva,Heidi Hassel Pettersen et al.
Camilla Tøvik Jørgensen et al.
Background: Abdominal vein thrombosis (AVT) is an uncommon manifestation of venous thromboembolism (VTE). Data pertaining to management and the clinical course of AVT are limited. ...
Alexa Loncharich,Kelsey Bria,Amber Afzal
Alexa Loncharich
Direct oral anticoagulants (DOACs) were historically avoided in cirrhosis due to concerns regarding impaired hepatic metabolism, cumulative toxicity, and the systematic exclusion of patients with cirrhosis from pivotal randomized trials. Ho...
Prolonged D-dimer elevation after COVID-19: diagnostic noise or residual risk in suspected pulmonary embolism? [0.03%]
COVID-19后D-二聚体持续升高：诊断噪声还是疑似肺栓塞的残留风险？
Nikola Milovanovic,Aleksandra Zivanic,Ivona Vranic Jovanovic et al.
Nikola Milovanovic et al.
Association between history of preeclampsia and biomarkers of endothelial dysfunction but not hypercoagulability (PERLA-Brazil study) [0.03%]
子痫前期史与内皮功能障碍生物标志物的相关性（而非高凝血标志物）——PERLA-巴西研究
Thaíse Emilia Moreira da Silva,Danyelle Romana Alves Rios,Letícia Gonçalves Silva et al.
Thaíse Emilia Moreira da Silva et al.
Assessment of quality of life in people with hemophilia on coagulation factor prophylaxis in Brazil [0.03%]
巴西血友病患者接受凝血因子预防治疗的生活质量评估
Nathália Martins Beserra,Ricardo Mesquita Camelo,Vanessa Meinertz Kaiser et al.
Nathália Martins Beserra et al.
Global perspectives on the core elements of Antithrombotic Stewardship in hospital [0.03%]
从全球视角看医院抗栓治疗合理化的关键因素
Julianne Chong,Vivien M Chen,Asad E Patanwala et al.
Julianne Chong et al.
Background: Anticoagulants are a leading cause of medication-related harm, with bleeding and thrombotic events from suboptimal use causing significant patient morbidity. Antithrombotic Stewardship (ATS) is a coordinated, ...
Inflammatory burden and solid-phase antiphospholipid antibodies independently associate with lupus anticoagulant positivity: A real-world laboratory cohort study [0.03%]
炎症负荷和固相抗磷脂抗体独立与狼疮抗凝血素阳性相关：一项真实世界实验室队列研究
Nikolaos Androulakis,Olga Striligka,Eleni Nioti et al.
Nikolaos Androulakis et al.
Matrix metalloproteinase 2 (MMP-2) and cardiovascular events in atrial fibrillation patients: A nested case control study from the ATHERO-AF cohort [0.03%]
心房颤动患者基质金属蛋白酶2(MMP-2)与心血管事件：ATHERO-AF队列中例证-based 病例对照研究
Danilo Menichelli,Emanuela Falcinelli,Pasquale Pignatelli et al.
Danilo Menichelli et al.
Atrial fibrillation (AF) is associated with an increased risk of major adverse cardiovascular events (CVEs) including myocardial infarction, ischemic stroke and peripheral arterial ischemic events despite optimal anticoagulant therapy. Matr...